Table 1.
Median (range) | |
---|---|
Age (years) | 65 (32–93) |
Days of symptoms before CT | 5 (1–16) |
WBC (N × 103/μL) | 5.54 (2.33–13.14) |
ANC (N × 103/μL) | 3.73 (1.17–11.15) |
ALC (N × 103/μL) | 1.07 (0.48–2.49) |
AMC (N × 103/μL) | 0.38 (0.13–1.33) |
N:L ratio | 3.52 (0.88–21.0) |
CD3+ cells (N × 103/μL) | 756 (288–1941) |
CD4+ cells (N × 103/μL) | 446 (194–1188) |
CD8+ cells (N × 103/μL) | 322 (53–1025) |
CD19+ cells (N × 103/μL) | 112 (35–224) |
CD16+ cells (N × 103/μL) | 172 (32–777) |
CD4+/CD8+ ratio | 1.80 (0.60–9.30) |
Hb (g/L) | 13 (8.80–17.70) |
PLTs | 203.50 (92–444) |
ESR (mm 1 h) | 67 (2–116) |
CRP (mg/dl) | 4.15 (0.03–18.80) |
Ferritin | 549 (23.40–5031.60) |
Ferritin:ESR ratio | 7.79 (0.32–213.20) |
D-dimer | 1 (0.27–18.30) |
Fibrinogen | 555 (228–1021) |
LDH | 300 (96–998) |
Procalcitonin | 0.09 (0.02–1.97) |
PaO2/FiO2 | 229.50 (95–523) |
Severity ScoreA | 6 (1–13) |
Severity Score B | 6 (1–18) |
Gender | N (%) |
F | 22 (36) |
M | 39 (64) |
Number of comorbidities | |
0 | 11 (18) |
1 | 14 (23) |
2 | 14 (23) |
3 | 7 (11) |
4 | 6 (10) |
5 or more | 9 (15) |
No. of lobes affected | |
1 | 2 (3) |
2 | 7 (11) |
3 | 7 (11) |
4 | 9 (15) |
5 | 36 (59) |
Bilateral lung disease | 58 (95) |
Type of parenchymal lesions | |
Neither ground glass opacities nor consolidation | 0 (0) |
Ground glass opacities only | 32 (52) |
Consolidation only | 0 (0) |
Ground glass opacities and consolidation | 29 (48) |
Septal thickening | 46 (75) |
Pleural effusion | 11 (18) |
Mediastinal lymph node enlargement | 20 (33) |
Outcome | |
Discharged | 56 (92) |
With ICU admission | 5 (9) |
Without ICU admission | 51 (91) |
Deceased | 5 (8) |
CT computed tomography, WBC white blood cells, ANC absolute neutrophil count, ALC absolute lymphocyte count, AMC absolute monocyte count, N:L neutrophils:lymphocytes, Hb haemoglobin, PLT platelets, ESR erythrocyte sedimentation rate, CRP C reactive protein, LDH lactate dehydrogenase, ICU intensive care unit.